• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
NeoGenomics, Inc. (NEO) Stock Price, News & Analysis

NeoGenomics, Inc. (NEO) Stock Price, News & Analysis

Currency in USD Disclaimer

$16.39

$1

(6.5%)

Day's range
$15.39
Day's range
$16.43
50-day range
$12.77
Day's range
$16.77
  • Country: US
  • ISIN: US64049M2098
52 wk range
$12.77
Day's range
$21.22
  • CEO: Mr. Christopher Michael Smith BSc
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.81
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (NEO)
  • Company NeoGenomics, Inc.
  • Price $16.39
  • Changes Percentage (6.5%)
  • Change $1
  • Day Low $15.39
  • Day High $16.43
  • Year High $21.22

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

  • Last Earnings 12/15/2020
  • Ex-Dividend for 5/16 Dividend 12/17/2020
  • Dividend Payable 12/30/2020
  • Today N/A
  • Next Earnings (Estimated) 02/18/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $19.00
  • High Stock Price Target $54.00
  • Low Stock Price Target $15.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.66
  • Trailing P/E Ratio -19.71
  • Forward P/E Ratio -19.71
  • P/E Growth -19.71
  • Net Income $-87,968,000

Income Statement

Quarterly

Annual

Latest News of NEO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

NeoGenomics, Inc. Frequently Asked Questions

  • What were the earnings of NEO in the last quarter?

    In the last quarter NeoGenomics, Inc. earnings were on Tuesday, November, 5th. The NeoGenomics, Inc. maker reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.04.

  • What is the NeoGenomics, Inc. stock price today?

    Today's price of NeoGenomics, Inc. is $16.39 — it has increased by +6.5% in the past 24 hours. Watch NeoGenomics, Inc. stock price performance more closely on the chart.

  • Does NeoGenomics, Inc. release reports?

    Yes, you can track NeoGenomics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the NeoGenomics, Inc. stock forecast?

    Watch the NeoGenomics, Inc. chart and read a more detailed NeoGenomics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is NeoGenomics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by NeoGenomics, Inc. stock ticker.

  • How to buy NeoGenomics, Inc. stocks?

    Like other stocks, NEO shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is NeoGenomics, Inc.'s EBITDA?

    NeoGenomics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in NeoGenomics, Inc.’s financial statements.

  • What is the NeoGenomics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.1486842572, which equates to approximately -14.87%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in NeoGenomics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including NeoGenomics, Inc.'s financials relevant news, and technical analysis. NeoGenomics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for NeoGenomics, Inc. stock currently indicates a “sell” signal. For more insights, review NeoGenomics, Inc.’s technical analysis.

  • A revenue figure for NeoGenomics, Inc. for its last quarter?

    NeoGenomics, Inc. published it's last quarterly revenues at $167.82 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.